growing at more than twice the rate of other prescription medicines In 2013, a record 260 therapeutics won orphan designations in the United States alone as science, policy, and pricing are fueling the trend for drugmakers to develop expensive drugs for small patient populations. We spoke to Jon Gardner, author of a new report from EvaluatePharma, about the growth of the orphan drug market, how successful drugmakers have been at expanding the use of these drugs for non-orphan indications, and whether growing pricing pressure will lead to disruptions in the market for these products.
By The Bio Report

Dr. Nathan E. Lewis of the Novo Nordisk Foundation Center for Biosustainability at UCSD School of Medicine speaks to CHI on November 3, 2014. Dr. Lewis will be a speaker during theAmerican Society for Microbiology

Dr. Joshua LaBaer of Arizona State University speaks to CHI on October 27, 2014. Dr. LaBaer will be a keynote speaker during the Recombinant Protein Expression and Production conference at PepTalk, January 19-23, 2015 in San Diego, CA. Topics include applications of sequence-verified recombination-based clone sets to high-throughput protein expression, cell-free expression systems, sharing clones upon request for research, self-assembling protein microarrays and more.
By Cambridge Healthtech Podcasts

The National Science Foundation and the National Institutes of Health, concerned about seeing the science they fund commercialized, have embraced the Lean Startup method as a way to improve the odds of success for new companies. Steve Blank, whose work launched the Lean Startup movement, has long worked with entrepreneurs, but last year began working with life sciences startups